Role of Contrast-Enhanced CT in Head and Neck Cancer Diagnosis

Introduction to Contrast-Enhanced CT

The American Academy of Otolaryngology-Head and Neck Surgery recommends contrast-enhanced CT of the neck as the primary imaging modality for diagnosing suspected head and neck malignancies in adults, but it has no role in cancer screening, and should only be ordered when clinical findings suggest increased malignancy risk 1, 2

The American College of Radiology suggests that contrast-enhanced CT neck is indicated for patients with neck masses present for more than 2 weeks without infectious etiology, persistent symptoms, high-risk features, or palpable cervical lymphadenopathy requiring evaluation 1, 3, 4, 5
The American Academy of Otolaryngology-Head and Neck Surgery recommends that clinicians order contrast-enhanced CT neck for any adult neck mass deemed at increased malignancy risk, providing accurate tumor thickness measurements and nodal staging comparable to MRI 1, 2, 4, 6, 7

The Journal of the American College of Radiology states that the technical requirements for contrast-enhanced CT neck include coverage from the skull base to the aortic arch, IV iodinated contrast, thin slices with multiplanar reformats using both soft tissue and bone algorithms, and optimal tumor contrast occurring 50-75 seconds after contrast injection start 2, 6

The American Academy of Otolaryngology-Head and Neck Surgery notes that CT is preferred as the primary imaging modality because it is more readily available than MRI, costs considerably less, has shorter scan time, and is better tolerated by claustrophobic patients, with an acceptable radiation dose of 3 mSv in adults 1, 2, 8

The Journal of Clinical Oncology suggests that CT alone may be insufficient when perineural invasion or skull base involvement is suspected, and MRI with gadolinium provides superior soft tissue contrast and perineural spread detection 1, 4, 8

The Journal of the American College of Radiology recommends that PET/CT is not sufficient for initial staging alone but is recommended as an adjunct for stage III-IV cancers to detect distant metastases and synchronous tumors, and should be used in conjunction with contrast-enhanced CT or MRI, not as a replacement 2, 6, 10